Efficacy of montelukast sodium chewable tablets combined with inhaled budesonide in treating pediatric asthma and its effect on inflammatory factors.

The aim of this study was to explore the clinical effect of montelukast sodium chewable tablets combined with inhaled budesonide in the treatment of pediatric asthma and its influence on inflammatory factors. One hundred and thirty-five asthmatic children were randomly divided into montelukast sodium group, budesonide group and combined group. Clinical symptoms, lung function, inflammatory factors and immune related indices of patients in each group were observed and recorded. After treatment, the times to disappearance of wheezes, dyspnea, asthma and hospital stay in the combined group were significantly shorter than those in the single-drug group (all p < 0.001). Forced vital capacity (FVC), forced expiratory volume in the first second (FEV1), peak expiratory flow (PEF) were significantly higher than those before treatment, and in the combined group value were significantly higher than in the single-drug group in the same period (all p < 0.001). Tumor necrosis factor-α (TNF-α), interleukin-4 (IL-4), IL-8 and hypersensitive C-reactive protein (hs-CRP) were significantly lower than before treatment, and the combined group was significantly lower than the single-drug group in the same period (all p < 0.05). The number of CD4+ and CD3+ cells in the combined group was significantly higher than that in the single-drug group, while the number of CD8 + cells and the expression level of immune globulin E (IgE) were significantly lower (all p < 0.05). There was no difference in the incidence of adverse reactions between the groups during treatment (p > 0.05). Six months after treatment, the incidence of asthma in the combined group was significantly lower than that in the single-drug group (both p < 0.05). Montelukast sodium chewable tablets combined with inhaled budesonide can shorten the discomfort duration of asthmatic children and help them restore lung function. Moreover, it reduces the level of inflammatory factors and increases the resistance of children, which is worthy of further promotion and application.

RCT Entities:   Population Interventions Outcomes